Sun Pharma Results: Sun Pharma Q2 results (2021-22) Review & News

Sun Pharma Results: Sun Pharma Q2 results (2021-22) Review & News

Last updated: 02 Nov, 2021 | 03:11 pm

Sun Pharma Results: Sun Pharma Q2 results (2021-22) Review & News

Profits above estimates: Sun Pharma has reported a net profit of Rs 2,047 crore for the quarter ended Sep, up 42% sequentially. Analysts had estimated a profit of about Rs 1,704 crore. In the year-ago period, the company had reported a net profit of Rs 1,813 crore. The strong numbers were the outcome of a low base.

Revenue rises: Revenue fell 1% sequentially to Rs 9,626 crore in the quarter ended Sep, beating the analysts’ forecast of Rs 9461.6 crore. On a yearly basis the revenue rose by 12.5% from Rs 8,553 crore in the same quarter last year.   

Margins expand: The operating performance was good and higher than expectations. EBITDA grew by 19.9% on-year to Rs 2,630 crore than Rs 2,219.7 estimated by the analysts. Margin expanded by 170 bps to 27.3% in the quarter ended Sep, beating estimates of 24.7%.

Sun Pharma Q2: Important highlights

Formulation sale: Sales of branded formulations in India for the Jul-Sep quarter were at Rs 3,187.8 crore, up by 26% over Q2 of last year, and accounting for 33% of total sales. The company's formulations sales in the US were at Rs 2,677 crore, a growth of 7.5% over the year ago quarter and accounting for about 28% of total sales. The company's sales in Emerging Markets were at Rs 1,800.5 crore for the Sep quarter, growing at 15.5% on year. Overall sales in Emerging Markets accounted for about 19% of total sales for the quarter. Formulation sales in Rest of World (ROW) markets were at Rs 1,392.6 crore up by 4.2% and accounted for approximately 15% of total sales.

Sun Pharma Q2 results Review:

Sun Pharma reported strong results for the Jul-Sep quarter due to a lower base of last year. During the quarter, Sun Pharma spent Rs 536.4 crore on research and development. The reduction is due to spill-over of certain clinical studies into subsequent quarters. The company remains steadfast in its focus on growing overall business and simultaneously strengthening the global specialty portfolio. The recent launch of Winlevi (acne) in the U.S. and Ilumya (psoriasis) in Canada is a step forward in this direction. 

Sun Pharma is ranked No.1 and has increased its market share to 8.1% in the Indian pharmaceutical market as per AIOCD AWACS MAT September-2021 report. For Jul-Sep quarter, the company launched 28 new products in the Indian market. Shares of Sun Pharma had surged around 3% after the results were announced but pared most of the gains to close 0.15% higher.

We are a SEBI registered investement advisor
Mutual Funds watchlist
aditya birla sun life flexi cap fund growth direct plan|ABSL low duration fund direct growth|axis bluechip fund direct growth|axis capital builder fund series 4|axis balanced advantage fund direct growth|axis equity saver fund direct growth|axis multicap fund direct growth|axis global innovation fund of fund direct growth|axis long term equity fund growth NAV|axis quant fund direct growth|axis small cap fund direct growth|axis value fund direct growth|baroda dynamic equity fund direct growth|BOI AXA bluechip fund|canara robeco flexi cap fund direct growth|canara robeco small cap fund direct growth|canara robeco value fund direct growth|DSP quant fund direct|franklin india smaller companies fund direct growth|HDFC arbitrage fund direct growth|HDFC balanced advantage fund direct growth|HDFC developed world index fund NAV|HDFC flexi cap fund direct growth|HDFC housing opportunities fund direct growth|HDFC hybrid equity fund direct growth|HDFC nifty 50 index fund|HDFC index fund sensex plan|HDFC mid cap opportunities direct plan growth|HDFC multi asset fund direct growth|HDFC small cap fund direct growth|HDFC top 100 fund direct growth|HSBC midcap fund direct growth|ICICI prudential balanced advantage fund|ICICI bluechip fund direct growth NAV|ICICI prudential commodities fund direct plan growth|ICICI nasdaq 100 fund direct growth|ICICI nifty next 50 index fund direct growth|ICICI small cap fund direct growth|ICICI prudential technology direct plan growth calculator|ICICI ultra short term fund direct growth|IDBI india top 100 equity fund direct growth|IDBI small cap fund direct growth|idfc us equity fund of fund direct growth|kotak short term fund direct growth|kotak emerging equity fund direct growth|kotak multicap fund direct growth|kotak global innovation fund of fund NAV|kotak gold fund direct growth|kotak savings fund direct growth|kotak small cap fund direct growth|L&T emerging businesses fund direct growth|mirae asset large cap fund direct growth|mirae asset midcap fund|motilal oswal nasdaq 100 fund of fund|navi nifty 50 index fund direct growth|nippon india banking and financial services fund direct growth|nippon banking fund direct|nippon india flexi cap fund NAV|nippon india large cap fund direct growth|nippon india pharma fund direct growth|nippon india small cap fund direct growth|PGIM small cap fund direct growth|quant flexi cap fund direct growth|quant infrastructure fund direct growth|quant tax plan direct plan growth|SBI bluechip fund direct growth|SBI corporate bond fund direct growth|SBI equity minimum variance fund direct growth|SBI flexi cap fund|SBI magnum children's benefit fund investment direct plan|SBI nifty index fund direct growth|SBI small cap fund direct growth|SBI technology opportunities fund direct growth|tata banking and financial services fund direct plan growth|tata business cycle fund|tata technology fund direct growth|tata equity pe fund direct growth|tata ethical fund direct growth NAV|tata focused fund direct growth|tata index fund nifty direct plan|tata india tax savings fund direct plan growth|UTI focused equity fund direct growth|UTI nifty index fund direct growth NAV|UTI nifty 50 index fund direct growth